Skip to main content

Monotherapy or combination antibiotic therapy in the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia

The Original Article was published on 30 May 2023

To the Editor,

We read with great interest the recent study by Dr. Foucrier et al. [1], in which they compared the efficacy of combination antibiotic therapy versus monotherapy in ICU patients with Pseudomonas aeruginosa ventilator-associated pneumonia (PA-VAP). A total of 169 patients were included, and they reported that the patients in the combination therapy group had similar outcomes to those in the monotherapy group (20/75 (26.6%) vs. 17/94 (18.1%), p = 0.180). Antibiotic management plays a key role in critical care [2]. We would like to add some comments.

First, this study is a secondary analysis of a previous randomized controlled trial, in which the sample size was calculated based on the comparison between long- and short-term antibiotic therapy in PA-VAP patients. Therefore, it remains unclear whether the sample size in the current cohort study is sufficient to detect the difference in the impact of combination therapy versus monotherapy on mortality in PA-VAP patients. In the current study, although the crude comparison was non-significant, there was an increasing trend of mortality in combination therapy (20/75 (26.6%) vs. 17/94 (18.1%), p = 0.180). We cannot rule out the risk that this non-significant finding was affected by underpowered sample size.

Second, several studies have also investigated the efficacy of combination and monotherapy in PA-VAP. For instance, in a previous multicenter cohort study [3] including 183 PA-VAP patients, Dr. Montero et al. also reported that the overall mortality was comparable between the monotherapy and combination therapy groups, supporting the current study's findings. However, different from the present study, Dr. Montero et al. used the initial antibiotic therapy (when the pulmonary infection was suspected) as the grouping method (monotherapy or combination therapy), and all inappropriate therapies were adjusted according to the bacteria identification or antimicrobial susceptibility testing result. However, the current study's grouping method (definitive monotherapy or combination therapy) was based on the antibiotic regimens after adapting to the antimicrobial susceptibility testing result. Therefore, it is reasonable to infer that the difference in mortality between the monotherapy and combination therapy in the current study should be different from previous studies.

Third, in the current study, the definitive antibiotic therapy was left to the discretion of the physician according to usual care. In clinical practice [4], clinicians may be more likely to prescribe combination therapy for pandrug-resistant PA (PDR-PA) or difficult-to-treat resistance PA (DTR-PA) infection, which was also associated with increased mortality [5]. Therefore, in the multivariable analysis, we suggest that the proportion of patients with PDR-PA or DTR-PA also should be considered.

Availability of data and materials

Not applicable.

References

  1. Foucrier A, Dessalle T, Tuffet S, Federici L, Dahyot-Fizelier C, Barbier F, Pottecher J, Monsel A, Hissem T, Lefrant JY, et al. Association between combination antibiotic therapy as opposed as monotherapy and outcomes of ICU patients with Pseudomonas aeruginosa ventilator-associated pneumonia: an ancillary study of the iDIAPASON trial. Crit Care. 2023;27(1):211.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Martin-Loeches I, Leone M, Einav S. Antibiotic stewardship: dead bugs do not mutate. J Transl Int Med. 2022;10(4):290–3.

    Article  PubMed  Google Scholar 

  3. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, Barcenilla F, Escoresca-Ortega A, Ochoa M, Cayuela A, Rello J. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med. 2007;35(8):1888–95.

    Article  CAS  PubMed  Google Scholar 

  4. Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect. 2005;11(Suppl 4):17–32.

    Article  CAS  PubMed  Google Scholar 

  5. Huh K, Chung DR, Ha YE, Ko JH, Kim SH, Kim MJ, Huh HJ, Lee NY, Cho SY, Kang CI, et al. Impact of difficult-to-treat resistance in gram-negative bacteremia on mortality: retrospective analysis of nationwide surveillance data. Clin Infect Dis. 2020;71(9):e487–96.

    PubMed  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

None.

Author information

Authors and Affiliations

Authors

Contributions

YS raised the question, and XX was responsible for analysis and writing. All authors have reviewed and approved the manuscript.

Corresponding author

Correspondence to Yanfei Shen.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shen, Y., Xie, X. Monotherapy or combination antibiotic therapy in the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia. Crit Care 27, 364 (2023). https://doi.org/10.1186/s13054-023-04656-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13054-023-04656-7